OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Crafton on Secondary Surgical Cytoreduction in Ovarian Cancer

December 4th 2019

Sarah Crafton, MD, gynecologic oncologist, Allegheny Health Network, discusses secondary surgical cytoreduction in recurrent ovarian cancer.

Dr. Ocean on Impact of the PRODIGE 24/CCTG PA.6 Trial in Pancreatic Cancer

December 3rd 2019

Allyson Ocean, MD, discusses the impact of the phase III PRODIGE 24/CCTG PA.6 trial on patients with pancreatic cancer.

Dr. McBride on the Regulatory Pathway for Biosimilars in Oncology

December 3rd 2019

Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, clinical coordinator, Hematology/Oncology, The University of Arizona Cancer Center, clinical assistant professor, The University of Arizona College of Pharmacy, discusses the regulatory pathway for biosimilars in oncology.

Dr. Perales on CAR T-Cell Therapy in DLBCL and Follicular Lymphoma

December 3rd 2019

Miguel-Angel Perales, MD, discusses the use of CAR T-cell therapy in diffuse large B-cell lymphoma and transformed follicular lymphoma.

Dr. Benson on the Ongoing Research With Immunotherapy in mCRC

December 3rd 2019

Al B. Benson, MD, professor of medicine, Hematology and Oncology, Northwestern University Feinberg School of Medicine, discusses ongoing research with immunotherapy in metastatic colorectal cancer (mCRC).

Dr. Cohen on the ELEVATE-TN Trial in CLL

December 3rd 2019

Jonathon B. Cohen, MD, MS, associate professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, co-director, Lymphoma Program, and medical director, Infusion Services, Winship Cancer Institute of Emory University, discusses the design of the phase III ELEVATE-TN trial in chronic lymphocytic leukemia (CLL).

Dr. Stein on the Importance of MRD in AML

December 3rd 2019

Eytan M. Stein, MD, discusses the importance of measuring for measurable residual disease in acute myeloid leukemia.

Dr. Davis on IMvigor130 Trial in Metastatic Urothelial Cancer

December 3rd 2019

Nancy B. Davis, MD, discusses the results of the phase III IMvigor130 trial in metastatic urothelial cancer.

Dr. Hamilton on the KATHERINE Trial in HER2+ Breast Cancer

December 3rd 2019

Erika P. Hamilton, MD, discusses the results of the phase III KATHERINE trial in HER2-positive breast cancer.

Explaining the Variability of Biologics and Biosimilars

December 2nd 2019

Jim M. Koeller, MS, FHOPA, discusses the inherent variability of recombinant DNA technology behind biosimilars.

Dr. Cascone on Remaining Challenges With Perioperative Immunotherapy in NSCLC

November 28th 2019

Tina Cascone, MD, PhD, discusses remaining challenges with perioperative immunotherapy in non–small cell lung cancer.

Dr. Patel on Sequencing Therapy in Rectal Cancer

November 28th 2019

Timil Patel, MD, discusses an optimal sequencing strategy in rectal cancer.

Dr. Beckermann on TKI/Immunotherapy Combinations in mRCC

November 28th 2019

Kathryn E. Beckermann, MD, PhD, discusses treatment selection in metastatic renal cell carcinoma.

Dr. Crafton on Optimizing Treatment Selection in Recurrent Ovarian Cancer

November 28th 2019

Sarah Crafton, MD, gynecologic oncologist, Allegheny Health Network, discusses optimizing treatment selection in recurrent ovarian cancer.

Dr. Tiacci on Vemurafenib and Rituximab Combo in Hairy Cell Leukemia

November 28th 2019

Enrico Tiacci, MD, discusses updated data of a phase II trial investigating the combination of vemurafenib and rituximab for patients with relapsed/refractory hairy cell leukemia.

Dr. Levy on First-Line Treatment for Nondriver NSCLC

November 28th 2019

Benjamin P. Levy, MD, discusses first-line treatment for patients with nondriver non–small cell lung cancer.

Dr. Patel on CheckMate-227 Results in Advanced NSCLC

November 27th 2019

Jyoti D. Patel, MD, discusses the results of the CheckMate-227 trial, which looked at an immunotherapy combination versus chemotherapy in patients with advanced non–small cell lung cancer.

Dr. Morris on Safety Profiles of AR Inhibitors in Prostate Cancer

November 27th 2019

David Morris, MD, FACS, discusses the safety profiles and common adverse events related to the androgen receptor inhibitors apalutamide, enzalutamide, and darolutamide for prostate cancer.

Dr. McBride on the Emergence of Biosimilars in Oncology

November 27th 2019

Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, discusses factors that need to be taken into consideration as biosimilars emerge in oncology.

Dr. Giralt on Current Standard of Care for Newly Diagnosed Multiple Myeloma

November 27th 2019

Sergio A. Giralt, MD, discusses the current frontline standard of care for patients with multiple myeloma.